Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | ABL2 | P42684 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30760914 | 1.00 | SRC (0.47) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL30760919 | 1.00 | SRC (0.47) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL30760868 | 1.00 | SRC (0.47) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL15156055 | 0.89 | SRC (0.55) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL15145742 | 0.89 | SRC (0.55) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL14798023 | 0.86 | SRC (0.48) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL31626196 | 0.86 | SRC (0.48) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL16321781 | 0.86 | SRC (0.49) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL16321782 | 0.86 | SRC (0.49) | SRCEGFRABL1ABL2TGFBR1 | |
| SCHEMBL28881338 | 0.85 | SRC (0.50) | SRCEGFRABL1ABL2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024037527-A1 | BTK DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-02-22 | — | — | WO | disclosed |